Stock listing
NASDAQ:LPCN Lipocine Inc. Stock
Home listing (NASDAQ) of Lipocine Inc.
Follow Lipocine Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:LPCN
$1.48 USD -0.04 (-2.6%)
Close on Nov 20, 2026
- Day range
- $1.43 – $1.55 USDNov 20, 2026
- Volume
- 215,726 sharesNov 20, 2026
- Market cap
- $16.39M USDAt the close on Nov 20, 2026 · price × 11.07M shares outstanding
- 52-week range
- $1.37 – $12.37 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.89M USDMedian day 71,956 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LPCN · Home | $1.48 USD | -0.04 (-2.6%) | 215,726 | $1.43 | $1.549 | $1.43 | $1.52 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LPCN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.48 | -0.04 | -2.6% | $1.43 | $1.549 | $1.43 | 215,726 | |
| $1.52 | -0.08 | -5.0% | $1.60 | $1.62 | $1.51 | 59,603 | |
| $1.60 | -0.06 | -3.6% | $1.64 | $1.68 | $1.57 | 71,956 | |
| $1.66 | -0.05 | -2.9% | $1.71 | $1.75 | $1.63 | 126,728 | |
| $1.71 | +0.09 | +5.6% | $1.63 | $1.75 | $1.53 | 214,107 | |
| $1.62 | +0.03 | +1.9% | $1.561 | $1.63 | $1.52 | 93,267 | |
| $1.59 | 0.00 | 0.0% | $1.62 | $1.64 | $1.56 | 206,506 | |
| $1.59 | -0.13 | -7.6% | $1.66 | $1.69 | $1.56 | 158,543 | |
| $1.72 | +0.15 | +9.6% | $1.597 | $1.74 | $1.58 | 259,430 | |
| $1.57 | +0.04 | +2.6% | $1.59 | $1.63 | $1.50 | 507,633 | |
| $1.53 | +0.09 | +6.3% | $1.47 | $1.59 | $1.406 | 415,968 | |
| $1.44 | -0.02 | -1.4% | $1.50 | $1.50 | $1.425 | 101,749 | |
| $1.46 | +0.01 | +0.7% | $1.42 | $1.50 | $1.42 | 188,277 | |
| $1.45 | +0.01 | +0.7% | $1.45 | $1.46 | $1.365 | 247,846 | |
| $1.44 | -0.08 | -5.3% | $1.50 | $1.50 | $1.42 | 111,917 | |
| $1.52 | +0.01 | +0.7% | $1.51 | $1.559 | $1.50 | 139,013 | |
| $1.51 | +0.05 | +3.4% | $1.46 | $1.54 | $1.46 | 193,298 | |
| $1.46 | +0.01 | +0.7% | $1.49 | $1.49 | $1.425 | 127,603 | |
| $1.45 | +0.01 | +0.7% | $1.44 | $1.45 | $1.40 | 108,521 | |
| $1.44 | -0.02 | -1.4% | $1.42 | $1.48 | $1.41 | 218,100 | |
| $1.46 | -0.14 | -8.8% | $1.56 | $1.60 | $1.43 | 354,800 | |
| $1.60 | -0.02 | -1.2% | $1.59 | $1.64 | $1.581 | 159,600 | |
| $1.62 | +0.09 | +5.9% | $1.54 | $1.66 | $1.537 | 244,700 | |
| $1.53 | -0.03 | -1.9% | $1.51 | $1.57 | $1.40 | 323,400 | |
| $1.56 | -0.12 | -7.1% | $1.66 | $1.68 | $1.48 | 405,900 | |
| $1.68 | -0.01 | -0.6% | $1.64 | $1.69 | $1.59 | 264,400 | |
| $1.69 | +0.07 | +4.3% | $1.69 | $1.71 | $1.60 | 374,300 | |
| $1.62 | -0.04 | -2.4% | $1.64 | $1.74 | $1.61 | 500,400 | |
| $1.66 | -0.06 | -3.5% | $1.705 | $1.77 | $1.59 | 877,600 | |
| $1.72 | -0.21 | -10.9% | $1.89 | $1.90 | $1.72 | 1,056,700 | |
| $1.93 | -0.27 | -12.3% | $2.05 | $2.05 | $1.89 | 2,322,300 | |
| $2.20 | +0.10 | +4.8% | $2.95 | $3.15 | $2.07 | 105,835,900 | |
| $2.10 | +0.03 | +1.4% | $2.08 | $2.10 | $2.07 | 12,800 | |
| $2.07 | +0.02 | +1.0% | $2.07 | $2.135 | $2.07 | 19,800 | |
| $2.05 | -0.02 | -1.0% | $2.08 | $2.13 | $2.05 | 38,900 | |
| $2.07 | -0.13 | -5.9% | $2.19 | $2.19 | $2.07 | 71,200 | |
| $2.20 | +0.04 | +1.9% | $2.14 | $2.25 | $2.08 | 31,400 | |
| $2.16 | +0.07 | +3.3% | $2.09 | $2.21 | $2.09 | 24,300 | |
| $2.09 | -0.01 | -0.5% | $2.07 | $2.21 | $2.06 | 34,400 | |
| $2.10 | +0.01 | +0.5% | $2.12 | $2.182 | $2.06 | 32,800 | |
| $2.09 | -0.03 | -1.4% | $2.10 | $2.178 | $2.08 | 32,600 | |
| $2.12 | -0.04 | -1.9% | $2.15 | $2.18 | $2.12 | 90,900 | |
| $2.16 | -0.08 | -3.6% | $2.13 | $2.22 | $2.12 | 64,300 | |
| $2.24 | +0.03 | +1.4% | $2.19 | $2.25 | $2.18 | 16,700 | |
| $2.21 | -0.01 | -0.5% | $2.20 | $2.25 | $2.12 | 48,500 | |
| $2.22 | +0.06 | +2.8% | $2.16 | $2.22 | $2.10 | 43,900 | |
| $2.16 | -0.025 | -1.1% | $2.23 | $2.235 | $2.15 | 64,000 | |
| $2.185 | -0.035 | -1.6% | $2.20 | $2.24 | $2.15 | 50,500 | |
| $2.22 | -0.05 | -2.2% | $2.20 | $2.27 | $2.15 | 27,300 | |
| $2.27 | +0.02 | +0.9% | $2.29 | $2.30 | $2.25 | 10,400 | |
| $2.25 | 0.00 | 0.0% | $2.315 | $2.345 | $2.25 | 9,400 | |
| $2.25 | -0.11 | -4.7% | $2.34 | $2.353 | $2.25 | 4,800 | |
| $2.36 | -0.09 | -3.7% | $2.39 | $2.40 | $2.345 | 21,100 | |
| $2.45 | +0.03 | +1.2% | $2.421 | $2.48 | $2.361 | 23,100 | |
| $2.42 | +0.065 | +2.8% | $2.41 | $2.50 | $2.32 | 26,500 | |
| $2.355 | +0.055 | +2.4% | $2.22 | $2.39 | $2.22 | 34,200 | |
| $2.30 | +0.06 | +2.7% | $2.19 | $2.30 | $2.183 | 10,000 | |
| $2.24 | +0.07 | +3.2% | $2.14 | $2.29 | $2.14 | 27,500 | |
| $2.17 | -0.06 | -2.7% | $2.23 | $2.23 | $2.13 | 19,500 | |
| $2.23 | +0.08 | +3.7% | $2.17 | $2.30 | $2.17 | 41,500 | |
| $2.15 | 0.00 | 0.0% | $2.15 | $2.29 | $2.15 | 106,000 | |
| $2.15 | +0.09 | +4.4% | $2.08 | $2.16 | $2.07 | 11,800 | |
| $2.06 | -0.03 | -1.4% | $2.07 | $2.10 | $2.05 | 26,700 | |
| $2.09 | 0.00 | 0.0% | $2.11 | $2.11 | $2.06 | 18,200 | |
| $2.09 | +0.04 | +2.0% | $2.05 | $2.135 | $2.05 | 35,200 |
Splits
2 splits since 2013 · NASDAQ:LPCN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-17 | Consolidation | |
| 1-for-100 | Consolidation |
- Ticker
- NASDAQ:LPCN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 42 slides
Latest news
Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Nov 10, 2026
Closed $1.59 (-7.6%) on Nov 10, 2026
Lipocine Announces Financial Results for the Third Quarter of 2026
Nov 5, 2026
Closed $1.53 (+6.3%) on Nov 5, 2026
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
Oct 7, 2026
Closed $2.20 (+4.8%) on Oct 7, 2026
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Sep 14, 2026
Closed $2.22 (-2.2%) on Sep 14, 2026
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 10, 2026
Closed $2.25 (0.0%) on Sep 10, 2026
Lipocine Appoints Michael J. Grissinger to Board of Directors
Aug 3, 2026
Closed $2.11 (-0.5%) on Aug 3, 2026
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Jun 4, 2026
Closed $2.21 (+0.9%) on Jun 4, 2026
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
May 19, 2026
Closed $2.20 (-0.5%) on May 19, 2026
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
May 18, 2026
Closed $2.21 (-2.2%) on May 18, 2026
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
May 7, 2026
Closed $2.37 (-0.8%) on May 8, 2026
Lipocine Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 138 in all · newest Nov 10, 2026 · oldest 2019
- Decks
- 153 decks · latest October 2026
Where Lipocine Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LPCN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:LPCN | BOATS | United States | USD |
Valuation
EV/sales −1.4× against a median of 4.7×: the lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$5.07M USD
- P/E
- Loss
- EV/sales
- −1.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.8×
- Gross margin
- Not reported
- Operating margin
- −269.1%
- Net margin
- −249.2%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.18
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Lipocine Inc. · NASDAQ:LPCN | US$16.39M | −US$5.07M | n/a | −1.4× | n/a | 0.8× | −249.2% | 0.0× | 1.18 |
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Initiator Pharma A/S · OMXSTO:INIT | US$16.76M | US$15.67M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Neurotech International Ltd. · ASX:NTI | US$16.63M | US$15.06M | n/a | n/a | n/a | 41.1× | n/a | 0.0× | n/a |
| Akari Therapeutics PLC · NASDAQ:AKTX | US$16.41M | US$10.66M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.49 |
| MaaT Pharma · EURONEXT:MAAT | US$16.11M | US$23.36M | n/a | 4.7× | n/a | n/a | −686.6% | n/a | n/a |
| Elicera Therapeutics AB · OMXSTO:ELIC | US$16.11M | US$10.42M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| Pasithea Therapeutics Corp. · NASDAQ:KTTA | US$16.00M | −US$25.22M | n/a | n/a | −0.1× | 0.4× | n/a | 0.0× | 0.97 |
| Atossa Therapeutics, Inc. · NASDAQ:ATOS | US$15.92M | −US$4.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.87 |
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| Celularity Inc. · NASDAQ:CELU | US$15.02M | US$50.46M | n/a | 2.7× | n/a | n/a | −117.3% | n/a | 1.47 |
| Median of the others | US$16.11M | US$11.52M | 4.7× | −0.1× | 1.7× | −178.5% | 0.0× | 0.97 |
Forecasts
1 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.20 · 1 analyst
- Revenue, year to Dec 2026
- 2.75M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Mahesh V. Patel | President & Chief Executive Officer |
| Benjamin Bruno | VP of Clinical Development |
| Nachiappan Chidambaram | VP Product Development |
| Anthony DelConte | Chief Medical Director |
| Krista Fogarty | Principal Accounting Officer & Corporate Controller |
Board
| Director | Role |
|---|---|
| R. Dana Ono | Chairman of the Board |
| Jill M. Jene | Director |
| John W. Higuchi | Director |
| Mahesh V. Patel | President & Chief Executive Officer |
| Michael Grissinger | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | +6.3% |
| Q2 2026 | Aug 4, 2026 · Before open | +0.9% |
| Q1 2026 | May 7, 2026 · Before open | −1.6% |
| Q4 2025 | Mar 10, 2026 | +14.1% |
| Q3 2025 | Nov 6, 2025 · Before open | +3.1% |
| Q2 2025 | Aug 14, 2025 · Before open | +0.8% |
| Q1 2025 | May 8, 2025 · Before open | −2.0% |
| Q4 2024 | Mar 5, 2025 · Before open | +10.1% |
| Q3 2024 | Nov 7, 2024 · Before open | −7.8% |
| Q2 2024 | Aug 8, 2024 · Before open | −12.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | +8.0% |
| Q4 2023 | Mar 7, 2024 · Before open | +1.4% |
| Q3 2023 | Nov 8, 2023 · Before open | −1.2% |
| Q2 2023 | Aug 10, 2023 · Before open | −1.6% |
| Q1 2023 | May 11, 2023 · Before open | +7.1% |
| Q4 2022 | Mar 10, 2023 · Before open | −26.7% |
| Q3 2022 | Nov 9, 2022 · Before open | −5.9% |
| Q2 2022 | Aug 8, 2022 · Before open | −11.1% |
| Q1 2022 | May 9, 2022 · Before open | −2.2% |
| Q4 2021 | Mar 9, 2022 · Before open | +6.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 42 slides | October 2026 |
| H.C. Wainwright 28th Annual Global Investment Conference 2026 | Conference | 22 slides | September 2026 |
| Technical Presentation (June 2026) | Technical | 46 slides | Jun 12, 2026 |
| Investor Presentation (May 2026) | Investor deck | 58 slides | May 7, 2026 |
| ASCP 2026 | Conference | 15 slides | May 2026 |
| Investor Presentation (May 2026) | Investor deck | 59 slides | May 2026 |
| Investor Presentation (April 2026) | Investor deck | 47 slides | Apr 2, 2026 |
| Investor Presentation (April 2026) | Investor deck | 21 slides | April 2026 |
| Investor Presentation (March 2026) | Investor deck | 8 slides | March 2026 |
| Investor Presentation (March 2026) | Investor deck | 4 slides | March 2026 |
Show 50 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2026) | Investor deck | 7 slides | March 2026 |
| Investor Presentation (March 2026) | Investor deck | 13 slides | March 2026 |
| Investor Presentation (March 2026) | Investor deck | 5 slides | March 2026 |
| Investor Presentation (March 2026) | Investor deck | 6 slides | March 2026 |
| Investor Presentation (March 2026) | Investor deck | 5 slides | March 2026 |
| Investor Presentation (February 2026) | Investor deck | 44 slides | Feb 18, 2026 |
| Investor Presentation (January 2026) | Investor deck | 38 slides | Jan 12, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 8 slides | January 2026 |
| Investor Presentation (November 2025) | Investor deck | 47 slides | Nov 18, 2025 |
| Investor Presentation (September 2025) | Investor deck | 37 slides | Sep 26, 2025 |
| H.C. Wainwright 27th Annual Global Investment Conference 2025 | Conference | 25 slides | Sep 5, 2025 |
| BIO 2025 | Conference | 17 slides | August 2025 |
| BIO 2025 | Conference | 9 slides | August 2025 |
| BIO 2025 | Conference | 10 slides | August 2025 |
| BIO 2025 | Conference | 13 slides | August 2025 |
| Technical Presentation (July 2025) | Technical | 42 slides | Jul 9, 2025 |
| Investor Presentation (July 2025) | Investor deck | 60 slides | July 2025 |
| Bio International Convention 2025 | Conference | 17 slides | June 2025 |
| Investor Presentation (May 2025) | Investor deck | 58 slides | May 12, 2025 |
| Investor Presentation (May 2025) | Investor deck | 28 slides | May 2025 |
| Investor Presentation (May 2025) | Investor deck | 9 slides | May 2025 |
| BIO 2025 | Conference | 9 slides | May 2025 |
| BIO 2025 | Conference | 9 slides | May 2025 |
| Investor Presentation (April 2025) | Investor deck | 54 slides | Apr 3, 2025 |
| Investor Presentation (February 2025) | Investor deck | 47 slides | Feb 11, 2025 |
| Investor Presentation (January 2025) | Investor deck | 46 slides | Jan 13, 2025 |
| Investor Presentation (December 2024) | Investor deck | 45 slides | Dec 13, 2024 |
| Technical Presentation (October 2024) | Technical | 35 slides | Oct 16, 2024 |
| H.C. Wainwright 5th Annual MASH Investor Conference 2024 | Conference | 22 slides | Oct 8, 2024 |
| EASL Congress (June 2024) | Conference | 24 slides | Jun 10, 2024 |
| Investor Presentation (April 2024) | Investor deck | 43 slides | Apr 29, 2024 |
| Technical Presentation (April 2024) | Technical | 18 slides | Apr 11, 2024 |
| Investor Presentation (March 2024) | Investor deck | 41 slides | Mar 7, 2024 |
| Investor Presentation (January 2024) | Investor deck | 29 slides | Jan 9, 2024 |
| Biotech Showcase 2024 | Conference | 8 slides | 2024 |
| EASL Congress 2024 | Conference | 24 slides | 2024 |
| Technical Presentation (November 2023) | Technical | 22 slides | Nov 13, 2023 |
| Investor Presentation (October 2023) | Investor deck | 28 slides | Oct 24, 2023 |
| Technical Presentation (July 2023) | Technical | 21 slides | Jul 27, 2023 |
| Investor Presentation (June 2023) | Investor deck | 36 slides | Jun 26, 2023 |
This page holds 50 of 153 decks. Open Decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.98M | 11.2M | -2.85M | 500.0K | 16.1M | 0 | 165.0K | 428.0K | 0 | 0 |
| Cost of revenue | 8.58M | 41.1K | 10.2M | 8.56M | 7.67M | 9.75M | 7.47M | 6.46M | 11.0M | 8.08M |
| Gross profit | -6.61M | 11.2M | -13.0M | -8.06M | 8.48M | -9.75M | -7.30M | 428.0K | -11.0M | -8.08M |
| Research and development | 8.58M | 7.35M | 10.2M | 8.56M | 7.67M | 9.75M | 7.47M | 6.46M | 11.0M | 8.08M |
| Selling, general and administrative | 3.76M | 5.00M | 4.90M | 4.06M | 5.33M | 8.25M | 5.60M | 5.29M | 10.2M | 10.4M |
| Operating income | -10.4M | -1.16M | -17.9M | -12.1M | 3.15M | -18.0M | -12.9M | -11.3M | -21.2M | -19.2M |
| Depreciation and amortization | 60.8K | 41.1K | 28.7K | 9.45K | 380 | 3.55K | 15.4K | 18.6K | 28.4K | 32.0K |
| EBITDA | -10.3M | -1.11M | -17.9M | -12.1M | 3.15M | -18.0M | -12.9M | -11.3M | -21.2M | -19.2M |
| Interest expense | 0 | 27.1K | 203.3K | 386.6K | 766.7K | 0 | 0 | 0 | ||
| Income before tax | -9.63M | 9.03K | -16.4M | -10.8M | -634.2K | -21.0M | -13.0M | -11.7M | -21.0M | -19.0M |
| Income tax | 200 | 681 | 755 | 681 | 200 | 200 | 200 | 700 | 700 | 752 |
| Net income | -9.63M | 8.35K | -16.4M | -10.8M | -634.4K | -21.0M | -13.0M | -11.7M | -21.0M | -19.0M |
| Earnings per share, basic | -1.77 | 0.00 | -3.10 | -2.06 | -0.01 | -0.38 | -0.50 | -0.55 | -1.05 | -1.04 |
| Earnings per share, diluted | -1.69 | -3.14 | -2.15 | -0.01 | -0.38 | -0.50 | -0.55 | -1.05 | -1.04 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.21M | 6.21M | 4.77M | 3.15M | 2.95M | 19.2M | 9.73M | 8.08M | 3.21M | 5.56M |
| Short-term investments | 9.72M | 15.4M | 17.3M | 29.4M | 41.7M | 450.0K | 4.34M | 7.17M | 18.3M | 21.3M |
| Receivables | 14.2K | 120.4K | 52.3K | 659.9K | 247.3K | 391 | 16.5K | 38.5K | 3.34M | 38.9K |
| Inventory | 1 | -41.9M | 5.00M | 5.00M | 0 | 0 | ||||
| Current assets | 16.9M | 22.3M | 22.9M | 34.1M | 46.4M | 25.3M | 19.6M | 20.8M | 25.2M | 27.2M |
| Property, plant and equipment | 104.3K | 165.1K | 116.1K | 131.6K | 7.21K | 3.55K | 19.0K | 75.1K | 103.4K | |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 17.0M | 22.5M | 23.0M | 37.5M | 52.5M | 25.4M | 19.7M | 20.9M | 25.3M | 27.3M |
| Accounts payable | 971.8K | 271.7K | 1.40M | 600.4K | 1.29M | 1.60M | 1.18M | 671.3K | 598.1K | 245.9K |
| Current liabilities | 2.53M | 1.51M | 2.63M | 1.68M | 5.62M | 6.58M | 4.96M | 4.49M | 6.35M | 1.33M |
| Long-term debt | 2.26M | 3.81M | 6.93M | 0 | 0 | |||||
| Total debt | 449.6K | 438.6K | 17.2K | 1.67M | 5.00M | 6.67M | 10.0M | 0 | ||
| Total liabilities | 2.53M | 1.51M | 2.63M | 1.91M | 6.91M | 10.0M | 13.4M | 11.4M | 6.35M | 1.33M |
| Shareholders' equity | 14.5M | 21.0M | 20.4M | 35.6M | 45.6M | 15.3M | 6.29M | 9.43M | 19.0M | 26.0M |
| Shares outstanding | 6.16M | 5.35M | 5.32M | 5.23M | 88.3M | 70.0M | 37.6M | 21.7M | 21.3M | 18.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9.76M | -1.22M | -11.9M | -12.0M | -4.41M | -15.3M | -11.7M | -12.1M | -16.7M | -18.3M |
| Capital spending | -1 | -90.1K | -13.2K | -133.8K | -7.59K | -7.59K | -7.59K | 0 | 0 | -59.6K |
| Free cash flow | -9.76M | -1.31M | -11.9M | -12.1M | -4.42M | -15.3M | -11.7M | -12.1M | -16.7M | -18.3M |
| Cash from investing | 5.89M | 2.45M | 13.1M | 14.3M | -43.8M | 3.89M | 3.00M | 11.3M | 3.13M | 3.23M |
| Cash from financing | 2.87M | 209.3K | 404.6K | -2.13M | 26.9M | 20.9M | 10.3M | 10.7M | 11.2M | 605.9K |
| Dividends paid | -211.4K | 0 | 0 | |||||||
| Share buybacks | -21.7K | 26.9M | 13.3M | 13.7M | 652.3K | 581.1K | 605.9K | |||
| Change in cash | -1.00M | 1.43M | 1.62M | 197.9K | -21.3M | 9.49M | 1.65M | 9.87M | -2.35M | -14.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 10, 2026 | Current report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 20, 2026 | Current report | SEC |
| 8-K · Current report | Oct 7, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 16, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 8-K · Current report | Sep 11, 2026 | Current report | SEC |
| 8-K · Current report | Sep 10, 2026 | Current report | SEC |
| 8-K/A · Current report, amended | Aug 21, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jun 9, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 4, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2026 | Current report | SEC |
| 8-K · Current report | May 26, 2026 | Current report | SEC |
| 8-K · Current report | May 19, 2026 | Current report | SEC |
| 8-K · Current report | May 18, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 7, 2026 | Current report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 21, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 2, 2026 | Current report | SEC |
| 8-K · Current report | Apr 2, 2026 | Current report | SEC |
| 8-K · Current report | Mar 10, 2026 | Results | SEC |
| 10-K · Annual report | Mar 9, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2026 | Current report | SEC |
| 424B5 · Prospectus | Feb 26, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 18, 2026 | Current report | SEC |
| 8-K · Current report | Feb 18, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 16, 2025 | Current report | SEC |
| 8-K · Current report | Dec 15, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 11, 2025 | Current report | SEC |
| 8-K · Current report | Nov 18, 2025 | Current report | SEC |
| 8-K · Current report | Nov 18, 2025 | Current report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Current report | SEC |
| 8-K · Current report | Sep 30, 2025 | Current report | SEC |
| 8-K · Current report | Sep 26, 2025 | Current report | SEC |
| 8-K · Current report | Sep 5, 2025 | Current report | SEC |
| 8-K · Current report | Sep 5, 2025 | Current report | SEC |
| 8-K · Current report | Aug 26, 2025 | Current report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 9, 2025 | Current report | SEC |
| 8-K · Current report | Jul 2, 2025 | Current report | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| 8-K · Current report | Jun 9, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 22, 2025 | Current report | SEC |
| 8-K · Current report | May 14, 2025 | Current report | SEC |
| 8-K · Current report | May 12, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Current report | SEC |
| 8-K · Current report | May 6, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 22, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 10, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 3, 2025 | Current report | SEC |
| 8-K · Current report | Mar 26, 2025 | Current report | SEC |
| 8-K · Current report | Mar 13, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2025 | Current report | SEC |
| 8-K · Current report | Feb 11, 2025 | Current report | SEC |
| 8-K · Current report | Feb 6, 2025 | Current report | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4/A · Change in ownership, amended | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 17, 2024 | Current report | SEC |
| 8-K · Current report | Dec 13, 2024 | Current report | SEC |
| 8-K · Current report | Nov 18, 2024 | Current report | SEC |
| 8-K · Current report | Nov 7, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2024 | Current report | SEC |
| 8-K · Current report | Oct 31, 2024 | Current report | SEC |
| 8-K · Current report | Oct 22, 2024 | Material contract | SEC |
| 8-K · Current report | Oct 16, 2024 | Current report | SEC |
| 8-K · Current report | Oct 10, 2024 | Current report | SEC |
| 8-K · Current report | Oct 8, 2024 | Current report | SEC |
| 8-K · Current report | Oct 7, 2024 | Current report | SEC |
| 8-K · Current report | Oct 2, 2024 | Current report | SEC |
| 8-K · Current report | Sep 30, 2024 | Current report | SEC |
| 8-K · Current report | Sep 5, 2024 | Current report | SEC |
| 8-K · Current report | Aug 27, 2024 | Current report | SEC |
| 8-K · Current report | Aug 8, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K/A · Current report, amended | Aug 7, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 25, 2024 | Current report | SEC |
| 8-K · Current report | Jun 10, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 3, 2024 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Jun 3, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Current report | SEC |
| 8-K · Current report | May 8, 2024 | Current report | SEC |
| 8-K · Current report | May 1, 2024 | Current report | SEC |
| 8-K · Current report | Apr 29, 2024 | Current report | SEC |
| 8-K · Current report | Apr 26, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Apr 26, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 26, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 24, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Apr 23, 2024 | Offer document | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 11, 2024 | Current report | SEC |
| 8-K · Current report | Mar 28, 2024 | Current report | SEC |
| 8-K · Current report | Mar 25, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 7, 2024 | Current report | SEC |
| 8-K · Current report | Mar 7, 2024 | Results | SEC |
| 10-K · Annual report | Mar 7, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2024 | Current report | SEC |
| 8-K · Current report | Feb 12, 2024 | Current report | SEC |
| 8-K · Current report | Jan 18, 2024 | Material contract | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 8-K · Current report | Dec 19, 2023 | Current report | SEC |
| UPLOAD · Letter from the SEC | Nov 29, 2023 | Other filings | SEC |
| S-3 · Registration statement | Nov 22, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 13, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2023 | Current report | SEC |
| 8-K · Current report | Nov 1, 2023 | Current report | SEC |
| 8-K · Current report | Oct 26, 2023 | Current report | SEC |
| 8-K · Current report | Oct 23, 2023 | Current report | SEC |
| 8-K · Current report | Oct 6, 2023 | Current report | SEC |
| 8-K · Current report | Sep 19, 2023 | Current report | SEC |
| 8-K · Current report | Aug 10, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jul 27, 2023 | Current report | SEC |
| 8-K · Current report | Jun 26, 2023 | Current report | SEC |
| 8-K · Current report | Jun 26, 2023 | Current report | SEC |
| 8-K · Current report | Jun 23, 2023 | Current report | SEC |
| 8-K · Current report | Jun 14, 2023 | Current report | SEC |
| 8-K · Current report | Jun 7, 2023 | Current report | SEC |
| 8-K · Current report | May 31, 2023 | Current report | SEC |
| 4 · Change in ownership | May 25, 2023 | Insider trade | SEC |
| 8-K · Current report | May 16, 2023 | Current report | SEC |
| 4 · Change in ownership | May 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2023 | Insider trade | SEC |
| 8-K · Current report | May 11, 2023 | Meeting outcome | SEC |
| 8-K · Current report | May 11, 2023 | Current report | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2023 | Current report | SEC |
| 424B5 · Prospectus | Apr 3, 2023 | Offer document | SEC |
| 8-K · Current report | Apr 3, 2023 | Management or board change | SEC |
| DEF 14A · Proxy statement | Mar 27, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2023 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 20, 2023 | Annual report | SEC |
| 4 · Change in ownership | Mar 17, 2023 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Mar 17, 2023 | Meeting notice | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| 10-K · Annual report | Mar 10, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
This page holds 200 of 826 filings. Open Filings
Cap table
Built by 6ix from Lipocine Inc.’s releases · as of Nov 4, 2026
- Common shares
- 11,073,439
- Fully diluted
- 11,073,439
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 11,073,439 | Nov 4, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 4, 2026 | 11,073,439 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Michael Grissinger Other companies: Aprea Therapeutics, Inc. (Director · Since at least May 16, 2022); Adicet Bio, Inc. (Director · Since at least Nov 5, 2018); Akari Therapeutics PLC (Director · Jan 1, 2024 – Jun 28, 2024 · Past) | Director · Since at least Aug 3, 2026 |
| Morgan Brown Other companies: Clene Inc. (Chief Financial Officer · Since at least Feb 1, 2022); World Heart Corp (Executive VP · Aug 10, 2009 – Sep 1, 2011 · Past); NPS Pharmaceuticals Inc (Vice President, Finance · Jan 17, 2006 – Oct 17, 2006 · Past) | Chief Financial Officer · Sep 16, 2013 – Dec 7, 2021 · Past |
| Spyros Papapetropoulos Other companies: Neuphoria Therapeutics Inc. (President and CEO, Director · Since at least Jul 1, 2024); Vigil Neuroscience Inc (Chief Medical Officer · Jan 6, 2022 – Nov 18, 2022 · Past); Adamas Pharmaceuticals Inc (Director · Nov 22, 2020 – Nov 24, 2021 · Past) | Director · Since at least Apr 11, 2022 |
| Stephen A Hill Other companies: Cellectar Biosciences, Inc. (Director · Aug 14, 2014 – Jun 24, 2020 · Past); Gyre Therapeutics, Inc. (Director · Dec 1, 2012 – Sep 6, 2018 · Past); ArQule Inc (President and CEO, Director · Jan 19, 2006 – Oct 4, 2007 · Past) | Director · Jan 6, 2014 – Dec 16, 2020 · Past |
| Jyrki Mattila Other companies: BioSpecifics Technologies Corp (Director · Mar 15, 2018 – May 22, 2019 · Past); Recro Pharma Inc (Executive VP, Business Dev. · Aug 21, 2017 – Jan 2, 2018 · Past) | Chief Business Officer · Jan 5, 2016 – Jan 26, 2017 · Past |
| Jill M. Jene Other companies: PDL BioPharma Inc (VP, Business Development · Jun 8, 2018 – Jan 8, 2020 · Past) | Director · Since at least Apr 11, 2022 |
| Richard Dana Ono Other companies: Inhibitor Therapeutics Inc. (Director · Jun 24, 2014 – Dec 22, 2020 · Past) | Director · Since at least Jan 6, 2014 |
| Anthony DelConte | Chief Medical Director · Since at least Nov 5, 2026 |
| Benjamin Bruno | VP of Clinical Development · Since at least Jun 4, 2026 |
| George Nomikos | Chief Medical Officer · Nov 1, 2022 – Nov 1, 2022 · Past |
All 20 people
| Person | Seat |
|---|---|
| Gregory Brooks Bass | Chief Commercial Officer · Feb 1, 2017 – Dec 29, 2017 · Past |
| Israel Menahem Vizel | President, Treasurer and Sec'y, Director · Feb 12, 2012 – Feb 12, 2012 · Past |
| Jeffrey Arvin Fink | Director · Since at least Jun 12, 2019 |
| John W. Higuchi | Director · Since at least Jul 24, 2013 |
| Krista Fogarty | Principal Accounting Officer · Since at least Jan 19, 2022 |
| Mahesh V. Patel | President & Chief Executive Officer · Since at least Jul 24, 2013 |
| Nachiappan Chidambaram | VP Product Development · Since at least Nov 5, 2026 |
| R. Dana Ono | Chairman of the Board · Since at least Aug 3, 2026 |
| Robert K Merrell | VP Finance · Jul 24, 2013 – Dec 10, 2013 · Past |
| Srinivasan Venkateshwaran | VP RandD · Jul 24, 2013 – Aug 14, 2014 · Past |
Log in to ask 6ix AI your own questions about Lipocine Inc.